Alnylam Pharmaceuticals said this week that it has launched the InterfeRx licensing program for its RNAi intellectual property.
The program, said the com- pany, will grant licenses for the development of RNAi therapeutics under Alnylam’s portfolio of issued and pending patents. One of those, which Alnylam holds exclusively, is the so-called Tuschl-2 patent application. This IP describes the two-to-three nucleotide 3’ overhanging ends on the end of certain siRNAs used for RNAi.